DexCom (NASDAQ:DXCM) Cut to Hold at StockNews.com

DexCom (NASDAQ:DXCM) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

A number of other research firms have also commented on DXCM. Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. UBS Group lifted their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James lifted their target price on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $141.40.

DexCom Price Performance

Shares of DXCM opened at $137.87 on Tuesday. The firm’s fifty day simple moving average is $130.58 and its 200-day simple moving average is $117.88. DexCom has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $53.15 billion, a price-to-earnings ratio of 105.25, a PEG ratio of 2.26 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the business earned $0.34 EPS. DexCom’s revenue for the quarter was up 26.9% compared to the same quarter last year. Equities analysts forecast that DexCom will post 1.76 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 over the last quarter. Company insiders own 0.41% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Capital World Investors lifted its position in shares of DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after buying an additional 5,256,092 shares during the last quarter. Norges Bank bought a new position in shares of DexCom in the 4th quarter worth about $540,178,000. Artisan Partners Limited Partnership lifted its position in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after buying an additional 3,672,471 shares during the last quarter. Capital Research Global Investors lifted its position in shares of DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after buying an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of DexCom in the 4th quarter worth about $231,773,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.